# Safety and Efficacy of VSJ-110 in the Treatment of Allergic Conjunctivitis in Adults With a History of Ocular Allergies

> **NCT04622345** · PHASE2 · COMPLETED · sponsor: **Vanda Pharmaceuticals** · enrollment: 47 (actual)

## Conditions studied

- Allergic Conjunctivitis

## Interventions

- **DRUG:** VSJ-110
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04622345
- **Lead sponsor:** Vanda Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-21
- **Primary completion:** 2021-05-22
- **Final completion:** 2021-06-28
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2025-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04622345

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04622345, "Safety and Efficacy of VSJ-110 in the Treatment of Allergic Conjunctivitis in Adults With a History of Ocular Allergies". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04622345. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*